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http://breast-cancer-research.com/content/15/5/R95RESEARCH ARTICLE Open AccessImpact of breast cancer subtypes on 3-year
survival among adolescent and young adult
women
Theresa H M Keegan1,2*, David J Press1, Li Tao1, Mindy C DeRouen1, Allison W Kurian2,3, Christina A Clarke1,2
and Scarlett L Gomez1,2Abstract
Introduction: Young women have poorer survival after breast cancer than do older women. It is unclear whether
this survival difference relates to the unique distribution of hormone receptor (HR) and human epidermal growth
factor receptor 2 (HER2)-defined molecular breast cancer subtypes among adolescent and young adult (AYA)
women aged 15 to 39 years. The purpose of our study was to examine associations between breast cancer
subtypes and short-term survival in AYA women, as well as to determine whether the distinct molecular subtype
distribution among AYA women explains the unfavorable overall breast cancer survival statistics reported for AYA
women compared with older women.
Methods: Data for 5,331 AYA breast cancers diagnosed between 2005 and 2009 were obtained from the California
Cancer Registry. Survival by subtype (triple-negative; HR+/HER2-; HR+/HER2+; HR-/HER2+) and age-group (AYA
versus 40- to 64-year-olds) was analyzed with Cox proportional hazards regression with follow-up through 2010.
Results: With up to 6 years of follow-up and a mean survival time of 3.1 years (SD = 1.5 years), AYA women
diagnosed with HR-/HER + and triple-negative breast cancer experienced a 1.6-fold and 2.7-fold increased risk of
death, respectively, from all causes (HR-/HER + hazard ratio: 1.55; 95% confidence interval (CI): 1.10 to 2.18;
triple-negative HR: 2.75; 95% CI, 2.06 to 3.66) and breast cancer (HR-/HER + hazard ratio: 1.63; 95% CI, 1.12 to 2.36;
triple-negative hazard ratio: 2.71; 95% CI, 1.98 to 3.71) than AYA women with HR+/HER2- breast cancer. AYA
women who resided in lower socioeconomic status neighborhoods, had public health insurance, and were of Black,
compared with White, race/ethnicity experienced worse survival. This race/ethnicity association was attenuated
somewhat after adjusting for breast cancer subtypes (hazard ratio, 1.33; 95% CI, 0.98 to 1.82). AYA women had similar
all-cause and breast cancer-specific short-term survival as older women for all breast cancer subtypes and across all
stages of disease.
Conclusions: Among AYA women with breast cancer, short-term survival varied by breast cancer subtypes, with the
distribution of breast cancer subtypes explaining some of the poorer survival observed among Black, compared with
White, AYA women. Future studies should consider whether distribution of breast cancer subtypes and other factors,
including differential receipt of treatment regimens, influences long-term survival in young compared with older
women.* Correspondence: theresa.keegan@cpic.org
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Breast cancer is the most frequently diagnosed cancer
among adolescent and young adult (AYA) women be-
tween 15 and 39 years of age, accounting for 14% of all
AYA cancer diagnoses [1] and 7% of all breast cancer
diagnoses [1,2]. Breast cancers are now recognized as
heterogeneous, based on tumor expression of receptors
for estrogen (ER), progesterone (PR)—referred to jointly
as hormone receptor (HR)—and human epidermal
growth factor receptor 2 (HER2) [3-5]. We recently re-
ported that AYA breast cancer incidence differs from
that in older women, with AYAs having higher propor-
tions of HR+/HER2+, triple-negative, and HR-/HER2+
breast cancer subtypes and higher proportions of pa-
tients of non-White race/ethnicity than older women
[6]. Compared with older women, AYAs also were more
likely to be diagnosed with stage III/IV disease and high-
grade tumors [6].
Several recent studies suggest that young age is an inde-
pendent predictor of poorer survival after breast cancer,
even after adjustment for sociodemographic and tumor
characteristics [7-14]. The HR+/HER2+ (Luminal B),
triple-negative, and HR-/HER2+ subtypes, found in higher
proportions among AYAs [6], generally are associated
with worse survival than the HR+/HER2- (Luminal A)
subtype [15,16], which could explain the overall poor
prognosis reported for AYA breast cancer patients.
However, only two, small institutionally based studies
have examined the extent to which differences in the
distributions of breast cancer subtypes explain the
lower survival among AYA patients. A 1989 through
2009 hospital-based study in Ireland did not find over-
all survival differences between AYAs (n = 276) and
older women when they adjusted for ER, PR, and HER2
status, although HER2 status was only 40% complete, and
these three tumor markers were adjusted for separately in
the analyses [17]. Conversely, an Italian, institution-based
study found worse survival in women <35 years of age
(n = 315) compared with older women (35 to 50 years
of age) for triple-negative, Luminal B, and HER2-
positive breast cancer, but not Luminal A breast cancer
[14]. To our knowledge, no previous population-based
study in the United States has considered survival by
molecular breast cancer subtypes among AYAs.
Therefore, by using population-based data from
California enriched with subtype information and pa-
tient sociodemographic data, we examined associa-
tions between breast cancer subtypes and short-term
overall and breast cancer-specific survival in AYAs.
Additionally, we sought to determine whether the dis-
tinct molecular-subtype distribution among AYAs [6]
could explain the unfavorable overall breast cancer
survival statistics reported for AYAs compared with
older women.Methods
Cancer cases
We obtained data from the California Cancer Registry
(CCR), which contributes approximately half of the data
in the National Cancer Institute’s Surveillance, Epidemiology,
and End Results (SEER) program and is estimated to
include more than 99% of all invasive cancers diag-
nosed in California. We included in our analysis all
female California residents diagnosed with invasive breast
cancer (International Classification of Disease for Oncology,
3rd Edition, (ICD-O-3) site codes C50.0-50.9) during
the period January 1, 2005, through December 31,
2009. Ethics approval for human-subjects research was
obtained from the California Prevention Institute of
California Institutional Review Board. As the analysis
was based on state-mandated cancer registry data, the
study was conducted in accordance with the waivers of
individual informed consent and HIPPA authorization.
For each breast cancer case, we obtained cancer registry
information routinely abstracted from the medical rec-
ord [18] on age at diagnosis, race/ethnicity (Hispanic,
non-Hispanic White, non-Hispanic Black, and non-
Hispanic Asian/Pacific Islander, hereafter referred to as
“White”, “Black”, “Hispanic”, and “Asian”), marital sta-
tus, American Joint Committee on Cancer (AJCC) stage
at diagnosis, tumor grade (low (I/II), high (III/IV)),
tumor size, lymph node involvement, metastasis status,
and ER, PR, and HER2 tumor-expression status. The
CCR has collected information on ER and PR since
1990 and on HER2 since 1999 [19]. ER and PR were
evaluated with dextran-coated charcoal assays or immu-
nohistochemistry (IHC); HER2 was tested with IHC or
fluorescence in situ hybridization. The markers were re-
corded as positive, negative, borderline, not tested, not re-
corded, or unknown, on the basis of pathology or medical
record information at the reporting facility [20].
Before 2005, treatments driving pathologic testing for
HER2 were indicated for late-stage breast cancer only;
thus data completeness was low, only 59%; since then,
data completeness has increased to at least 83%. Because
of this data completeness, we limited our analyses to
cases diagnosed between 2005 and 2009.
We also obtained registry information on initial course
of treatment (surgery, chemotherapy, and radiation ther-
apy), primary source of payment to the hospital at the
time of initial diagnosis and/or treatment (health insur-
ance), census-block group of residence at diagnosis, and
vital status (routinely determined by the CCR through
hospital follow-up and database linkages, including the
Social Security Administration) as of December 31, 2010,
and, for the deceased, the underlying cause of death.
As information on patient education or other individual-
level measures of socioeconomic status (SES) are not col-
lected by the CCR, we assigned a previously developed
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at time of diagnosis that incorporates 2000 Census
block group on education, occupation, unemployment,
household income, and poverty [21]. Each cancer case
was then assigned to a neighborhood SES quintile
based on the distribution of SES across all census block
groups in California. Health insurance was grouped
into public insurance (Medicaid and other government-
assisted programs), private insurance (health maintenance
organizations, preferred provider organizations, managed
care not otherwise specified, and military care), no insur-
ance, and insurance status unknown [22].
Of the 6,463 California females diagnosed with breast
cancer between 15 and 39 years of age and between
2005 and 2009, we excluded cases with in situ breast
cancer (n = 752), Paget disease (n < 5), mammographic
or xerographic diagnosis only, or no mass found (n = 12),
breast cancer as a non-first primary (n = 364), and autopsy
or death certificate only (n < 5). The resulting study popu-
lation included 5,331 AYA patients. For analyses compar-
ing AYAs with older women, we followed the same
inclusion criteria, which resulted in 53,860 women from
40 to 64 years of age.
Categorization of breast cancer subtypes
Breast cancer subtypes were categorized according to
tumor expression of ER, PR, and HER2. HR+/HER2-
was defined as ER or PR positive and HER2 negative;
HR+/HER2+ as ER or PR positive and HER2 positive;
HR-/HER2+ as ER and PR negative and HER2 positive;
and triple-negative as ER, PR, and HER2 negative [3-5].
Participants who had missing or borderline ER and PR
or HER2 and could not be defined in these four categor-
ies were considered unclassified (Table 1).
Statistical analyses
To evaluate differences in survival by breast cancer sub-
types, we conducted survival analyses with Cox propor-
tional hazards regression to estimate hazard ratios and
associated 95% confidence intervals (95% CIs). For de-
ceased patients, survival time was measured in days
from the date of diagnosis to the date of death from any
cause for overall survival or to the date of death from
breast cancer for breast cancer-specific survival. Patients
who died of other causes were censored at the time of
death for analyses of breast cancer-specific survival. Pa-
tients alive at the study end date (December 31, 2010)
were censored at this time or at date of last follow-up
(that is, last known contact); 96% of censored patients
had a follow-up date within 2 years of the study end
date.
The proportional hazards assumption was examined
by statistical testing of the correlation between weighted
Schoenfeld residuals and logarithmically transformedsurvival time. No violations of the assumption were ob-
served. Multivariate Cox regression models included
cancer registry variables significant at P < 0.05 in univari-
ate models (age at diagnosis, subtype, race/ethnicity,
marital status, tumor grade, lymph node involvement,
tumor size, neighborhood SES, health insurance status,
surgery, and radiation therapy) or with a priori hypoth-
eses for inclusion (for example, chemotherapy). Models
were conducted with and without breast cancer subtype,
and AJCC stage was included as a stratifying variable.
Effect modification between breast cancer subtypes and
race/ethnicity, tumor grade, lymph node involvement,
neighborhood SES, and health insurance status was
assessed by including an interaction term in the multi-
variable model; a significant interaction (P < 0.05) was
found between subtype and tumor grade. Hazard ratio
and 95% CI estimates for comparing AYAs with women
40 to 64 years of age were presented by stage of diagno-
sis for comparison with prior studies [1,8]. Analyses
were carried out by using SAS software version 9.3 (SAS
Institute, Cary, NC, USA). All P values reported are
two-sided, and those that were <0.05 were considered to
be statistically significant.
Results
HR+/HER2- was the most commonly diagnosed subtype
(41.1%) among AYA breast cancer patients, followed
by triple-negative (19.0%), HR+/HER2+ (15.2%), and
HR-/HER2+ (8.8%) (Table 1). In this California cohort,
most AYA patients were of White (42.1%) or Hispanic
(32.6%) race/ethnicity; 62.5% of AYAs were diagnosed
between 35 and 39 years of age. The highest proportion of
stage III/IV disease occurred for the HR+/HER2+ and
HR-/HER2+ subtypes, and the highest proportion of high-
grade disease occurred for the HR-/HER2+ and triple-
negative subtypes. The proportion of AYA patients
who received chemotherapy ranged from 71.4% for
HR+/HER2- to 87.4% for triple-negative subtypes; the
proportions of AYAs who received surgery or radi-
ation were similar across subtypes.
With up to 6 years of follow-up and a mean survival
time of 3.1 years (SD = 1.5 years), AYAs diagnosed with
HR-/HER + and triple-negative breast cancer experi-
enced an approximately 1.6-fold and 2.7-fold increased
risk of death, respectively, from all causes (HR-/HER+
hazard ratio: 1.55; 95% CI, 1.10 to 2.18; triple-negative
HR: 2.75; 95% CI, 2.06 to 3.66) and breast cancer (HR-/
HER+ hazard ratio: 1.63; 95% CI, 1.12 to 2.36; triple-
negative hazard ratio: 2.71; 95% CI, 1.98 to 3.71) com-
pared with AYAs diagnosed with HR+/HER2-; however,
among AYAs, survival was similar between HR+/HER2-
and HR+/HER2+ breast cancer subtypes (Figure 1,
Table 2). Adjusting for breast cancer subtypes attenuated
the poorer survival experienced by Black, compared with
Table 1 Demographic and clinical characteristics for adolescents and young adults (15 to 39 years of age) with breast
cancer by subtype*, California, 2005 through 2009
Total HR+/HER2-* HR+/HER2+* HR-/HER2+* Triple negative Unclassified
(n = 5,331) (n = 2,191) (n = 811) (n = 469) (n = 1014) (n = 846)
Characteristics n (Col%) n (Col%) n (Col%) n (Col%) n (Col%) n (Col%)
Age at diagnosis
15-29 560 (10.5%) 190 (8.7%) 88 (10.9%) 63 (13.4%) 108 (10.7%) 111 (13.1%)
30-34 1,441 (27.0%) 525 (24.0%) 237 (29.2%) 141 (30.1%) 303 (29.9%) 235 (27.8%)
35-39 3,330 (62.5%) 1476 (67.4%) 486 (59.9%) 265 (56.5%) 603 (59.5%) 500 (59.1%)
Race/ethnicity**
NH White 2,247 (42.1%) 984 (44.9%) 321 (39.6%) 193 (41.2%) 404 (39.8%) 345 (40.8%)
NH Black 388 (7.3%) 128 (5.8%) 60 (7.4%) 37 (7.9%) 106 (10.5%) 57 (6.7%)
Hispanic 1,737 (32.6%) 645 (29.4%) 273 (33.7%) 163 (34.8%) 378 (37.3%) 278 (32.9%)
NH Asian/Pacific Islander 914 (17.1%) 423 (19.3%) 153 (18.9%) 74 (15.8%) 120 (11.8%) 144 (17.0%)
Other/unknown 45 (0.8%) 11 (0.5%) <5 <5 6 (0.6%) 22 (2.6%)
Marital status at diagnosis
Married 3,268 (61.3%) 1,338 (61.1%) 500 (61.7%) 320 (68.2%) 616 (60.7%) 494 (58.4%)
Never married 1,527 (28.6%) 639 (29.2%) 242 (29.8%) 104 (22.2%) 287 (28.3%) 255 (30.1%)
Previously married 380 (7.1%) 165 (7.5%) 56 (6.9%) 31 (6.6%) 83 (8.2%) 45 (5.3%)
Unknown 156 (2.9%) 49 (2.2%) 13 (1.6%) 14 (3.0%) 28 (2.8%) 52 (6.1%)
Tumor grade†
Low 2,090 (39.2%) 1,288 (58.8%) 323 (39.8%) 102 (21.7%) 91 (9.0%) 286 (33.8%)
High 2,891 (54.2%) 821 (37.5%) 455 (56.1%) 340 (72.5%) 888 (87.6%) 387 (45.7%)
Unknown/not stated 350 (6.6%) 82 (3.7%) 33 (4.1%) 27 (5.8%) 35 (3.5%) 173 (20.4%)
AJCC stage at diagnosis
I 1,310 (24.6%) 660 (30.1%) 170 (21.0%) 86 (18.3%) 191 (18.8%) 203 (24.0%)
II 2,328 (43.7%) 933 (42.6%) 354 (43.6%) 187 (39.9%) 515 (50.8%) 339 (40.1%)
III 1,100 (20.6%) 425 (19.4%) 214 (26.4%) 130 (27.7%) 208 (20.5%) 123 (14.5%)
IV 313 (5.9%) 115 (5.2%) 47 (5.8%) 47 (10.0%) 60 (5.9%) 44 (5.2%)
Unknown/not stated 280 (5.3%) 58 (2.6%) 26 (3.2%) 19 (4.1%) 40 (3.9%) 137 (16.2%)
Tumor size (cm)
<2.00 1,987 (37.3%) 969 (44.2%) 309 (38.1%) 147 (31.3%) 287 (28.3%) 275 (32.5%)
2.01-5.00 2,261 (42.4%) 915 (41.8%) 350 (43.2%) 196 (41.8%) 500 (49.3%) 300 (35.5%)
>5.00 734 (13.8%) 239 (10.9%) 115 (14.2%) 79 (16.8%) 176 (17.4%) 125 (14.8%)
Microinvasion 57 (1.1%) 12 (0.5%) 9 (1.1%) 17 (3.6%) 13 (1.3%) 6 (0.7%)
Diffuse 54 (1.0%) 15 (0.7%) 5 (0.6%) 7 (1.5%) 0 27 (3.2%)
Unknown 238 (4.5%) 41 (1.9%) 23 (2.8%) 23 (4.9%) 38 (3.7%) 113 (13.4%)
Lymph nodes involvement
No 2,563 (48.1%) 1,074 (49.0%) 333 (41.1%) 178 (38.0%) 532 (52.5%) 446 (52.7%)
Positive 2,647 (49.7%) 1,098 (50.1%) 470 (58.0%) 282 (60.1%) 468 (46.2%) 329 (38.9%)
Unknown 121 (2.3%) 19 (0.9%) 8 (1.0%) 9 (1.9%) 14 (1.4%) 71 (8.4%)
Metastasis status
No 4,880 (91.5%) 2,050 (93.6%) 751 (92.6%) 411 (87.6%) 936 (92.3%) 732 (86.5%)
Yes 316 (5.9%) 115 (5.2%) 47 (5.8%) 47 (10.0%) 61 (6.0%) 46 (5.4%)
Unknown 135 (2.5%) 26 (1.2%) 13 (1.6%) 11 (2.3%) 17 (1.7%) 68 (8.0%)
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Table 1 Demographic and clinical characteristics for adolescents and young adults (15 to 39 years of age) with breast
cancer by subtype*, California, 2005 through 2009 (Continued)
Surgery
No 362 (6.8%) 103 (4.7%) 47 (5.8%) 41 (8.7%) 64 (6.3%) 107 (12.6%)
Yes 4,942 (92.7%) 2,077 (94.8%) 763 (94.1%) 428 (91.3%) 944 (93.1%) 730 (86.3%)
Unknown 27 (0.5%) 11 (0.5%) <5 0 6 (0.6%) 9 (1.1%)
Chemotherapy
No 1,250 (23.4%) 588 (26.8%) 120 (14.8%) 67 (14.3%) 120 (11.8%) 355 (42.0%)
Yes 3,986 (74.8%) 1,565 (71.4%) 678 (83.6%) 395 (84.2%) 886 (87.4%) 462 (54.6%)
Unknown 95 (1.8%) 38 (1.7%) 13 (1.6%) 7 (1.5%) 8 (0.8%) 29 (3.4%)
Radiation therapy
No 2,818 (52.9%) 1,110 (50.7%) 415 (51.2%) 244 (52.0%) 503 (49.6%) 546 (64.5%)
Yes 2,509 (47.1%) 1,080 (49.3%) 396 (48.8%) 225 (48.0%) 511 (50.4%) 297 (35.1%)
Unknown <5 <5 0 0 0 <5
Neighborhood SES quintile
1, lowest 875 (16.4%) 328 (15.0%) 135 (16.6%) 73 (15.6%) 183 (18.0%) 156 (18.4%)
2 997 (18.7%) 392 (17.9%) 133 (16.4%) 97 (20.7%) 203 (20.0%) 172 (20.3%)
3 1,051 (19.7%) 411 (18.8%) 163 (20.1%) 103 (22.0%) 197 (19.4%) 177 (20.9%)
4 1,190 (22.3%) 524 (23.9%) 178 (21.9%) 100 (21.3%) 206 (20.3%) 182 (21.5%)
5, highest 1,218 (22.8%) 536 (24.5%) 202 (24.9%) 96 (20.5%) 225 (22.2%) 159 (18.8%)
Insurance status‡
Private/military insurance 3,637 (68.2%) 1564 (71.4%) 557 (68.7%) 310 (66.1%) 680 (67.1%) 526 (62.2%)
Public insurance 1,109 (20.8%) 408 (18.6%) 175 (21.6%) 109 (23.2%) 234 (23.1%) 183 (21.6%)
No insurance 93 (1.7%) 30 (1.4%) 16 (2.0%) 6 (1.3%) 13 (1.3%) 28 (3.3%)
Unknown 492 (9.2%) 189 (8.6%) 63 (7.8%) 44 (9.4%) 87 (8.6%) 109 (12.9%)
* Human epidermal growth factor receptor 2 (HER2), hormone receptor (HR), triple-negative (estrogen-receptor negative, progesterone-receptor negative, HER2-negative).
** Non-Hispanic.
† Low grade was defined as tumor grade I and II; high grade was defined as tumor grade III.
‡ Public insurance included Medicaid and other government-assisted programs; private insurance included health maintenance organizations, preferred provider
organizations, managed care not otherwise specified, and military care.
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cant, Black AYAs had a 33% increased risk of death
over Whites after adjustment for breast cancer subtype
(hazard ratio, 1.33; 95% CI, 0.98 to 1.82). AYA patients
residing in lower-SES neighborhoods generally had
poorer survival than did AYAs residing in the highest
SES neighborhood quintile, although not all of these as-
sociations remained statistically significant after strati-
fying by stage at diagnosis and adjusting for health
insurance and treatment. In particular, in models with-
out stage at diagnosis, health insurance, and treatment,
an 86% increased risk of death was found from all
causes (hazard ratio, 1.86; 95% CI, 1.32 to 2.61) and an
80% increased risk of death of breast cancer (hazard ra-
tio, 1.80; 95% CI, 1.24 to 2.63) among AYAs residing in
the lowest versus highest SES neighborhoods (data not
shown in tables). In addition, AYA patients with public,
compared with private, medical insurance also experi-
enced worse survival.We observed an interaction (P value = 0.02 for overall
survival and P value = 0.01 for breast cancer-specific sur-
vival) between breast cancer subtype and tumor grade
(Table 3). Among AYA patients diagnosed with low-
grade tumors, the risk of breast cancer death was nearly
14 times higher in women with triple-negative and 2
times higher in women with HR+/HER2+ compared
with HR+/HER2- breast cancer. For high-grade tumors,
AYAs diagnosed with triple-negative breast cancer had
more than two-fold increased risk of death, whereas
AYAs diagnosed with HR+/HER2+ breast cancer experi-
enced approximately half the risk of death, than did
AYAs diagnosed with HR+/HER2- breast cancer.
Overall, in models including only age group, AYA pa-
tients experienced a 30% increased risk of death from all
causes (hazard ratio, 1.30; 95% CI, 1.19 to 1.42) and 44%
increased risk of death from breast cancer (hazard ratio,
1.44; 95% CI, 1.30 to 1.59) than women 40 to 64 years of
age (data not shown in tables). Once models were
Figure 1 Overall survival for adolescents and young adults (15 to 39 years of age) and women aged 40 to 64 years with breast cancer
by subtype, California, 2005 through 2009.
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term all-cause (hazard ratio, 0.99; 95% CI, 0.90 to 1.08)
and breast cancer-specific survival (hazard ratio, 1.05;
95% CI, 0.96 to 1.16) to women 40 to 64 years of age
(data not shown in tables). Further adjustment for other
factors and breast cancer subtype did not appreciably
change these associations (all-cause survival hazard ra-
tio, 0.92; 95% CI, 0.83 to 1.02; breast cancer-specific sur-
vival hazard ratio, 0.94; 95% CI, 0.84 to 1.05) (Table 4).
AYAs demonstrated similar survival to older women for
all breast cancer subtypes, across all race/ethnicities,
and across all stages of disease (Table 4). Although not
statistically significant, AYAs with early stage I disease
may have poorer all-cause (hazard ratio, 1.44; 95% CI,
0.90 to 2.31) and breast cancer-specific survival (hazard
ratio, 1.38; 95% CI, 0.86 to 2.21) than women 40 to
64 years of age.
Discussion
Using recently available data on HER2-defined breast
cancer in the large, diverse California population, to
our knowledge, our study is the first to conduct a
population-based assessment of subtype-specific breast
cancer survival among AYA patients. AYAs diagnosed
with HR-/HER2+ and triple-negative breast cancer ex-
perienced poorer overall and breast cancer-specific sur-
vival than did AYAs diagnosed with HR+/HER2- breast
cancer. For AYAs diagnosed with HR+/HER2+ breast
cancer, prognosis varied by tumor grade, with the risk
of breast cancer death higher in low-grade disease and
lower in high-grade disease than AYAs diagnosed withHR+/HER2- breast cancer. In addition, poorer survival
outcomes were observed among AYAs who resided in
lower-SES neighborhoods, had public health insurance,
and who were of Black, compared with White, race/
ethnicity, although the race/ethnicity association was
attenuated somewhat after adjusting for breast cancer
subtypes. Furthermore, across all breast cancer sub-
types and after consideration for stage at diagnosis and
other factors, AYA women experienced similar short-
term survival compared with older women.
Prior studies reported younger age at diagnosis as an in-
dependent predictor of adverse prognosis [7,9-11,13,14].
Whereas our study found similar short-term survival
among AYAs and older women overall and for all breast
cancer subtypes, an institution-based study in Italy found
poorer survival in women <35 years for all subtypes, ex-
cept Luminal A breast cancer [14]. The poorer survival
among AYAs has been attributed to the lack of routine
screening among women younger than 40 years, whose
diagnoses tend to follow identification of a palpable mass
and concomitant differences in clinical presentation [23]
or differential receipt of treatment regimens previously
observed between AYAs and older age groups [11,24,25].
In particular, uncertainty exists regarding the optimal
endocrine therapy for premenopausal women, with
some clinical trials suggesting that more intensive ther-
apy, including ovarian suppression or ablation, im-
proves outcomes [26,27]. Despite the disproportionate
burden of advanced-stage disease at diagnosis among
AYA women [6], worse survival among AYA women
has been attributed to poorer outcomes with early-
Table 2 Risk of death from any cause or breast cancer among adolescents and young adults (15 to 39 years of age)
with breast cancer*, California, 2005 through 2009
All-cause deaths Breast cancer-specific deaths
Number of
deaths
Model 1* Model 2** Number of
deaths
Model 1* Model 2** †
HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI)
Subtype†
HR+/HER2- 124 N/A 1.00 (reference) 100 N/A 1.00 (reference)
HR+/HER2+ 46 0.77 (0.53-1.11) 40 0.80 (0.54-1.19)
HR-/HER2+ 73 1.55 (1.10-2.18) 66 1.63 (1.12-2.36)
Triple negative 194 2.75 (2.06-3.66) 166 2.71 (1.98-3.71)
Unclassified 97 1.34 (0.96-1.86) 82 1.37 (0.95-1.98)
Race/ethnicity‡
NH White 194 1.00 (reference) 1.00 (reference) 164 1.00 (reference) 1.00 (reference)
NH Black 77 1.55 (1.14-2.10) 1.33 (0.98-1.82) 67 1.57 (1.12-2.20) 1.35 (0.96-1.89)
Hispanic 199 1.08 (0.85-1.38) 1.06 (0.83-1.35) 172 1.15 (0.88-1.49) 1.12 (0.86-1.46)
NH Asian/Pacific Islander 61 0.99 (0.73-1.35) 1.00 (0.73-1.36) 48 0.98 (0.69-1.39) 0.98 (0.69-1.39)
Unknown <5 N/A N/A <5 N/A N/A
Marital status at diagnosis
Married 284 1.00 (reference) 1.00 (reference) 241 1.00 (reference) 1.00 (reference)
Never married 190 1.26 (1.01-1.58) 1.26 (1.01-1.57) 163 1.29 (1.01-1.64) 1.28 (1.01-1.63)
Previously married 41 1.18 (0.81-1.70) 1.09 (0.75-1.57) 35 1.17 (0.78-1.77) 1.08 (0.72-1.63)
Unknown 19 1.26 (0.74-2.15) 1.15 (0.67-1.95) 15 1.17 (0.64-2.15) 1.05 (0.58-1.93)
Tumor grade
Low 113 1.00 (reference) 1.00 (reference) 84 1.00 (reference) 1.00 (reference)
High 374 1.92 (1.52-2.43) 1.50 (1.17-1.93) 332 2.30 (1.76-3.01) 1.81 (1.36-2.41)
Unknown 47 1.01 (0.60-1.71) 0.84 (0.49-1.44) 38 1.12 (0.61-2.04) 0.92 (0.50-1.70)
Lymph nodes involvement
No 124 1.00 (reference) 1.00 (reference) 98 1.00 (reference) 1.00 (reference)
Positive 372 1.15 (0.87-1.52) 1.23 (0.93-1.62) 321 1.16 (0.85-1.58) 1.24 (0.91-1.70)
Unknown 38 0.86 (0.44-1.69) 0.84 (0.43-1.65) 35 1.11 (0.54-2.28) 1.10 (0.53-2.26)
Neighborhood SES quintile
5 (highest) 73 1.00 (reference) 1.00 (reference) 60 1.00 (reference) 1.00 (reference)
4 103 1.21 (0.87-1.68) 1.30 (0.93-1.80) 90 1.25 (0.88-1.79) 1.33 (0.93-1.90)
3 111 1.35 (0.97-1.87) 1.41 (1.01-1.95) 92 1.27 (0.88-1.82) 1.31 (0.91-1.88)
2 117 1.35 (0.97-1.88) 1.42 (1.02-1.98) 101 1.37 (0.96-1.96) 1.43 (1.00-2.06)
1 (lowest) 130 1.19 (0.84-1.70) 1.23 (0.86-1.75) 111 1.13 (0.77-1.66) 1.15 (0.78-1.70)
Insurance status×
Private/military insurance 272 1.00 (reference) 1.00 (reference) 222 1.00 (reference) 1.00 (reference)
Public insurance 192 1.53 (1.21-1.92) 1.52 (1.21-1.92) 171 1.64 (1.28-2.10) 1.63 (1.27-2.10)
No insurance 14 0.95 (0.49-1.83) 1.08 (0.56-2.09) 12 0.92 (0.44-1.92) 1.04 (0.50-2.17)
Unknown 56 1.33 (0.94-1.88) 1.33 (0.95-1.88) 49 1.48 (1.01-2.15) 1.45 (1.00-2.11)
* Cox models were adjusted for all variables in the table and age at diagnosis (continuous), tumor size (continuous), and first course of treatment (chemotherapy
(y/n), radiation (y/n), and surgery (y/n)); AJCC stage levels I through IV and unknown was included as a stratifying variable.
** Cox models were additionally adjusted for subtypes of breast cancer.
† Human epidermal growth factor receptor 2 (HER2), hormone receptor (HR), triple-negative (estrogen-receptor negative, progesterone-receptor
negative, HER2-negative).
‡ Non-Hispanic.
× Public insurance included Medicaid and other government-assisted programs; private insurance included health maintenance organizations, preferred provider
organizations, managed care not otherwise specified, and military care.
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Table 3 Risk of death of any cause or of breast cancer for adolescents and young adults (15 to 39 years of age) with
breast cancer by tumor grade*, California, 2005-2009
All-cause deaths Breast cancer-specific deaths
Number of deaths HR (95% CI)* Number of deaths HR (95% CI)*
Low tumor grade (I/II)
Subtype†
HR+/HER2- 44 1.00 (reference) 27 1.00 (reference)
HR+/HER2+ 19 1.57 (0.87-2.81) 16 2.23 (1.12-4.44)
HR-/HER2+ 9 1.52 (0.61-3.76) 7 2.37 (0.85-6.61)
Triple negative 25 10.64 (5.66-20.00) 21 13.87 (6.49-29.64)
Unclassified 16 1.34 (0.70-2.57) 13 2.05 (0.95-4.44)
High tumor grade (III)
Subtype†
HR+/HER2- 73 1.00 (reference) 67 1.00 (reference)
HR+/HER2+ 23 0.49 (0.29-0.81) 21 0.48 (0.28-0.81)
HR-/HER2+ 59 1.40 (0.95-2.06) 55 1.40 (0.93-2.10)
Triple negative 162 2.24 (1.61-3.13) 140 2.14 (1.51-3.04)
Unclassified 57 1.47 (0.98-2.21) 49 1.32 (0.85-2.05)
* Cox models were adjusted for all variables presented in Table 2 and age at diagnosis (continuous), tumor size (continuous), and first course of treatment
(chemotherapy (y/n), radiation (y/n), and surgery (y/n)); AJCC stage levels I-IV and unknown was included as a stratifying variable. P for interaction between breast
cancer subtype and grade = 0.018 for all-cause mortality and =0.0735 for breast cancer-specific mortality.
† Human epidermal growth factor receptor 2 (HER2), hormone receptor (HR), triple-negative (estrogen-receptor negative, progesterone-receptor negative,
HER2-negative).
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study. Overall, our findings suggest that differences in
stage at diagnosis between AYAs and older women [6]
explain the poorer short-term survival observed in
young women.
AYA breast cancer patients of Black race/ethnicity ex-
perienced worse short-term survival than did White
women of the same age. Poorer survival outcomes have
been reported among young Black women, who also ex-
perience a disproportionate burden of triple-negative
breast cancer, compared with young White women
[6,8,13,28]. Among AYAs, we previously reported that,
relative to Whites, Blacks were diagnosed with a higher
proportion of triple-negative breast cancer [6]. Although
adjusting for breast cancer subtype attenuated survival
disparities somewhat, Black AYAs still experienced
poorer survival than White AYAs. Black AYA and older
women experienced similar breast cancer-specific sur-
vival, underscoring the poorer survival of black women
seen at all ages [29].
Our findings of poorer survival among AYA breast
cancer patients living in lower SES neighborhoods is
supported by previous studies involving women of all
ages using SEER data [30-32]. Although explanations for
SES differences in survival are not well documented, ad-
vanced stage at diagnosis has been the most cited ex-
planatory factor [32,33]—perhaps because of screening
disparities among women age 40 to 79 years [34]—and
increasing evidence suggests inadequate breast cancertreatment and follow-up care among patients in lower
SES groups [33]. Furthermore, recent evidence suggests
that disparities in breast cancer treatment modalities are
associated with health insurance status [35-37], a meas-
ure we found to be associated with survival in our study.
Factors related to treatment receipt and stage at diagno-
sis, however, have not been found to explain fully the so-
cioeconomic disparities in survival [32,33,38,39]. Our
study observed neighborhood SES differences when we
controlled for stage at diagnosis, initial course of treat-
ment, and health insurance, although controlling for
these three factors attenuated our neighborhood SES
findings, particularly for the lowest SES neighborhoods.
SES inequalities in survival also may be influenced by
factors we could not measure in this study, such as
quality of treatment and follow-up care, and comorbidi-
ties [33].
Among AYAs, worse short-term survival for HR-/HER2+
and triple-negative breast cancers is consistent with prior
studies that had 5 or fewer years of follow up [14,40,41].
Studies with more than 5 years of follow-up have dem-
onstrated that triple-negative breast cancer may not
have the worst long-term survival outcomes among
subtypes [16,42-45], perhaps because of an early peak
of recurrence in the first few years after diagnosis and
a sharp decrease in the recurrence rate in subsequent
years [46]. Results from the population-based Carolina
Breast Cancer Study demonstrated that the risk of death
10 or more years after diagnosis was highest among
Table 4 Risk of death of any cause or of breast cancer, comparing younger women (15 to 39 years of age) with women 40
to 64 years of age with breast cancer, by subtype, race/ethnicity, or stage at diagnosis; California, 2005 through 2009
All-cause deaths Breast cancer-specific deaths
Model 1* Model 2** Model 1** Model 2**
HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI)
Overall 0.96 (0.86-1.06) 0.92 (0.83-1.02) 0.99 (0.88-1.10) 0.94 (0.84-1.05)
Subtype†
HR+/HER2- N/A 0.92 (0.75-1.11) N/A 0.92 (0.74-1.15)
HR+/HER2+ 0.87 (0.62-1.22) 1.00 (0.69-1.46)
HR-/HER2+ 0.99 (0.74-1.31) 1.08 (0.80-1.46)
Triple negative 0.93 (0.78-1.10) 0.93 (0.77-1.12)
Unclassified 0.86 (0.66-1.13) 0.88 (0.65-1.19)
Race/ethnicity‡
NH White 0.90 (0.76-1.06) 0.89 (0.75-1.05) 0.93 (0.78-1.12) 0.92 (0.77-1.11)
NH Black 0.93 (0.71-1.21) 0.89 (0.68-1.16) 0.97 (0.72-1.29) 0.91 (0.68-1.22)
Hispanic 1.01 (0.85-1.20) 0.95 (0.80-1.14) 1.05 (0.87-1.27) 0.99 (0.82-1.20)
NH Asian/Pacific Islander 1.01 (0.75-1.35) 0.98 (0.73-1.31) 1.02 (0.73-1.41) 0.98 (0.71-1.37)
Unknown N/A N/A N/A N/A
AJCC stage at diagnosis
I 0.97 (0.65-1.43) 0.95 (0.64-1.40) 1.44 (0.90-2.31) 1.38 (0.86-2.21)
II 0.95 (0.79-1.15) 0.90 (0.74-1.08) 0.98 (0.79-1.21) 0.91 (0.73-1.13)
III 1.02 (0.86-1.21) 0.97 (0.82-1.15) 1.06 (0.88-1.27) 1.01 (0.84-1.21)
IV 0.86 (0.70-1.06) 0.86 (0.70-1.05) 0.86 (0.69-1.07) 0.86 (0.69-1.07)
Unknown 1.10 (0.70-1.74) 1.09 (0.69-1.72) 1.02 (0.59-1.77) 1.03 (0.59-1.78)
* Reference group for each model was women 40 to 64 years of age at diagnosis. Cox models were adjusted for all variables in the table and year of diagnosis
(continuous), marital status at diagnosis, tumor grade, neighborhood SES (quintile), and first course of treatment (chemotherapy (y/n), radiation (y/n), and surgery
(y/n)). AJCC stage levels I through IV and unknown were included as a stratifying variable.
** Cox models were additionally adjusted for subtypes of breast cancer.
† Human epidermal growth factor receptor 2 (HER2), hormone receptor (HR), triple-negative (estrogen-receptor negative, progesterone-receptor negative, HER2-negative).
‡ Non-Hispanic.
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women [16,42]. Our finding of an interaction between
breast cancer subtype and tumor grade suggests that
low-grade triple-negative breast cancers, which are less
common, have substantially worse prognosis than low-
grade HR+/HER2- breast cancer. Furthermore, the higher
risk of breast cancer death in low-grade HR+/HER2+ dis-
ease and lower risk of death in high-grade HR+/HER2+
disease than HR+/HER2- disease could result from
women with high-grade HR+/HER2+ disease being
more likely than those with low-grade HR+/HER2+
disease to receive adjuvant trastuzumab, as suggested by
recent studies on patterns of care [47-49].
Our study is the first, to our knowledge, to use
population-based cancer registry data to examine sur-
vival by the four major molecular breast cancer subtypes
for AYA patients by race/ethnicity. As compared with
prior studies, ours had a relatively low percentage (16%)
of women whose breast cancers were unclassified be-
cause of missing ER, PR, or HER2 receptor information
[19,50]. To maximize the availability of HER2-receptorstatus, however, our study was restricted to diagnoses
between 2005 and 2009, limiting the number of AYAs
included and the survival time available. Although reli-
ability of ER and PR tests can be controversial [51], evi-
dence suggests that results from a centralized pathology
laboratory generally agree with registry reports for ER
and PR status [52]. However, HER2 testing between
community-based hospitals and centralized reference la-
boratories has been found to contain some disagreement
[53]. Consensus-based methods to improve laboratory
assays will continue to increase the reliability of ER, PR,
and HER2 tests over time [54,55]. As with other studies
that consider breast cancer subtype according to recep-
tor status, we may be limited, in that subtypes deter-
mined by ER, PR, and HER2 receptor status serve only
as a proxy for full genetic profiling. These ER, PR, and
HER2 designations, however, guide clinical treatment
[56] and are becoming increasingly useful in epidemio-
logic research [3,16,57]. Our study is also subject to the
potential misclassification of race/ethnicity, although we
have detected excellent overall agreement with self-
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agreement for Hispanics and Asians [58,59]. Although
we considered the first course of cancer-directed treat-
ment, we did not have details on treatment such as
chemotherapy components and regimen, or treatment
received after this period; therefore, our findings could
be subject to residual confounding from incomplete
treatment data in the cancer registry [60]. We also lacked
information about treatment failure or recurrence. Further-
more, our study did not have individual-level measures of
SES to consider separately or with our neighborhood
measure. Although neighborhood and individual SES
are associated, neighborhood SES has been found to
underestimate associations observed with individual-
level SES [61].
Conclusions
Among AYAs with breast cancer, short-term survival var-
ied by breast cancer subtypes, with AYAs diagnosed with
HR-/HER2+ and triple-negative breast cancer experien-
cing poorer short-term survival than AYAs diagnosed with
HR+/HER2- breast cancer. In addition, poorer survival
outcomes were observed among AYAs who resided in
lower SES neighborhoods, had public health insurance,
and who were of Black, compared with White, race/ethni-
city. Although differences in the breast cancer subtype dis-
tributions explained some of the worse survival observed
for Black compared with White AYAs, it is noteworthy
that AYA and older Black women had similar breast can-
cer survival, underscoring the poorer survival among
Black women at all ages. As follow-up data accrue, it will
be important to continue to monitor long-term survival
by breast cancer subtypes in the AYA population. We did
not observe short-term survival differences between AYAs
and older women after consideration for stage at diagno-
sis, but future studies should consider whether the distri-
bution of breast cancer subtypes and other factors,
including differential receipt of treatment regimens, influ-
ences long-term survival in young compared with older
women.
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